



Application for the following position in the EHRA Board:

EHRA TREASURER 2026-2028

1. Your Identity

Title: Prof., MD, FEHRA, FESC

Family Name(s): SCHERR

First Name(s): DANIEL

Birth Date: 02/08/1973

Institute/Organisation: Medical University Graz, Austria

Department: Division of Cardiology, University Heart Center Graz

Address: Auenbruggerplatz 15

Post Code/Zip: 8036

City: Graz

Country: Austria



2. General Curriculum Vitae (300 words max)- Please add your H index and top 10 publications in the last 5 years

General CV

1999: MD; Medical University of Graz, Austria

2006 - 2008: Research Fellowship in EP; Johns Hopkins University, Baltimore, USA (*PI Prof. Hugh Calkins*)

2010: Habilitation

2010 - 2012: EHRA 2-year EP Fellowship; CHU Bordeaux, France (*PIs Profs. Michel Haissaguerre & Pierre Jais*)

2015: EHRA Certified EP Specialist Level 2 (renewed 2025)

2017 - 2018: ESC/EHRA DAS CAM Fellowship, University Medical Center Maastricht, NL

2019 - ongoing: Professor of Cardiac Electrophysiology; Medical University of Graz, Austria

Current position: Head of Clinical EP & EP research group; Division of Cardiology/University Heart Center Graz; Austrian board certified MD in Cardiology, Internal Medicine, Intensive Care Medicine, Sports Medicine

2025 – ongoing: Associate Editor, Europace Journal

Top 10 publications of the last 5 years (H-Index: 38)

Scherr, D; Turagam, MK; Maury, P; Blaauw, Y; van, der, Voort, P; Neuzil, P; Reichlin, T; Metzner, A; Vijgen, J; Kautzner, J; Boveda, S; Anic, A; Hansen, J; Manninger, M; Sommer, P; Anselme, F; Willems, S; Deneke, T; Tilz, R; Steven, D; Wakili, R; Jais, P; Funasako, M; Arentz, T; Rollin, A; Mulder, BA; Ouss, A; Petru, J; Kueffer, T; Lemoine, MD; Koopman, P; Peichl, P; Adelino, R; Jurisic, Z; Ruwald, M; Eberl, AS; Sohns, C; Savoure, A; Nentwich, K; Gunawardene, M; Heeger, CH; Sultan, A; Bohnen, JE; Kupusovic, J; Derval, N; Lehmann, H; Ekanem, E; Reddy, VY *Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study.* Europace. 2025; 27(8): Doi: 10.1093/europace/eaaf012

Farkowski, MM*; **Scherr, D***; Boriani, G; Kazakiewicz, D; Haim, M; Huculeci, R; Malaczynska-Rajpold, K; Petersen, SE; Timmis, A; Traykov, V; Vardas, PE; Pürerfellner, H; Merino, JL *Arrhythmia care in ESC member countries: the 2025 ESC-EHRA atlas on heart rhythm disorders* Europace. 2025; 27(7): euaf124 Doi: 10.1093/europace/eaaf124

***shared first authorship**

De, Potter, T; **Scherr, D;** Pürerfellner, H; Račkauskas, G; Hansen, J; Vijgen, J; Philips, T; Knecht, S; Szeplaki, G; Van, Herendael, H; Kronborg, MB; Berte, B; Ruwald, M; Kollias, G; Lukac, P; Tan, T; Duytschaever, M *Dual energy for pulmonary vein isolation using focal ablation technology integrated with a three-dimensional mapping system: SmartFIRE 12-month results.* Europace. 2025; 27(9): Doi: 10.1093/europace/eaaf174



Heeger, CH; Almorad, A; **Scherr, D**; Szegedi, N; Seidl, S; Baran, J; Duytschaever, M; Gupta, D; Linz, D; Lyan, E; Rocca, DD; Gellér, L; Knecht, S; Calvert, P; Meilak, S; Leventopoulos, G; Popescu, SS; Rauber, M; Kollias, G; Niedzwiedz, M; Sarkozy, A; Badoz, M; Manninger-Wünscher, M; Sciacca, V; Sohns, C; Ginks, MR; Pürerfellner, H; Tilz, RR *Temperature-guided high and very high-power short duration ablation for atrial fibrillation treatment: the peQasus multicentre study.*

Europace. 2025; 27(6): Doi: 10.1093/europace/euae284

Timmis A, Aboyans V, Vardas P, Townsend N, Torbica A, Kavousi M, Boriani G, Huculeci R, Kazakiewicz D, **Scherr D**, Karagiannidis E, Cvijic M, Kapłon-Cieślicka A, Ignatiuk B, Raatikainen P, De Smedt D, Wood A, Dudek D, Van Belle E, Weidinger F; ESC National Cardiac Societies. *Eur Heart J.* 2024 Oct 7;45(38):4019-4062.

Benedikt, M; Oulhaj, A; Rohrer, U; Manninger, M; Tripolt, NJ; Pferschy, PN; Aziz, F; Wallner, M; Kolesnik, E; Gwechenberger, M; Martinek, M; Nürnberg, M; Roithinger, FX; Steinwender, C; Widkal, J; Leiter, S; Zirlik, A; Stühlinger, M; **Scherr, D**; Sourij, H; von, Lewinski, D *Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds.*

NEJM Evid. 2024; 3(10):EVIDoA2400147 Doi: 10.1056/EVIDoA2400147

Schuijt, E; **Scherr, D**; Plank, G; Schotten, U; Heijman, J *Evolution in electrophysiology 100 years after Einthoven: translational and computational innovations in rhythm control of atrial fibrillation.*

Europace. 2024; 27(1): Doi: 10.1093/europace/euae304

Kirchhof, P; Toennis, T; Goette, A; Camm, AJ; Diener, HC; Becher, N; Bertaglia, E; Blomstrom, Lundqvist, C; Borlich, M; Brandes, A; Cabanelas, N; Calvert, M; Chlouverakis, G; Dan, GA; de, Groot, JR; Dichtl, W; Kravchuk, B; Lubiński, A; Marijon, E; Merkely, B; Mont, L; Ozga, AK; Rajappan, K; Sarkozy, A; **Scherr, D**; Sznajder, R; Velchev, V; Wichterle, D; Sehner, S; Simantirakis, E; Lip, GYH; Vardas, P; Schotten, U; Zapf, A *Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.*

N Engl J Med. 2023; 389(13): 1167-1179. Doi: 10.1056/NEJMoa2303062

Ekanem, E; Reddy, VY; Schmidt, B; Reichlin, T; Neven, K; Metzner, A; Hansen, J; Blaauw, Y; Maury, P; Arentz, T; Sommer, P; Anic, A; Anselme, F; Boveda, S; Deneke, T; Willems, S; van, der, Voort, P; Tilz, R; Funasako, M; **Scherr, D**; Wakili, R; Steven, D; Kautzner, J; Vijgen, J; Jais, P; Petru, J; Chun, J; Roten, L; Fütting, A; Rillig, A; Mulder, BA; Johannessen, A; Rollin, A; Lehrmann, H; Sohns, C; Jurisic, Z; Savoure, A; Combes, S; Nentwich, K; Gunawardene, M; Ouss, A; Kirstein, B; Manninger, M; Bohnen, JE; Sultan, A; Peichl, P; Koopman, P; Derval, N; Turagam, MK; Neuzil, P, MANIFEST-PF, Cooperative; *Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF).*

Europace. 2022; 24(8):1256-1266 Doi: 10.1093/europace/euac050

Heidbuchel, H; Adami, PE; Antz, M; Braunschweig, F; Delise, P; **Scherr, D**; Solberg, EE; Wilhelm, M; Pelliccia, A. *Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions: Part 1: Supraventricular arrhythmias. A position statement of the Section of Sports Cardiology and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA), both associations of the European Society of Cardiology.*

Eur J Prev Cardiol. 2021; 28(14):1539-1551 Doi: 10.1177/2047487320925635



3. Describe previous experience(s) within EHRA, ESC or your National Cardiac Society

Being in EHRA for 20 years, I am grateful for all the opportunities this association has offered me, and for the many colleagues I have met, worked with, and learned from. **EHRA is a truly unique institution** that has had a profound and positive impact on my career and on my life. Most importantly, it has brought me lasting friendships with colleagues from many different countries and cultures.

I have had the privilege of serving EHRA in **various roles** that demand **dedication, teamwork, and passion**. Among these, my involvement with the EHRA National Cardiac Society Committee stands out. Organizing and supporting EHRA joint sessions, promoting membership, and contributing to the EHRA ATLAS project, together with colleagues from across Europe, has been a **personally rewarding experience**. I hope all these joint efforts achieved their goal of *promoting education, research, and patient care in EP*. I am equally passionate about mentorship within EHRA. Guiding younger colleagues and supporting their professional growth has been one of the most fulfilling aspects of my engagement.

Over the years, I have also worked in multiple other capacities within EHRA. These roles have provided me with a broad perspective on the structure, function, and collaborative spirit of EHRA.

EHRA:

- **Since 2005:** EHRA Member
- **2013-2025:** Member center, EHRA Research Network
- **2015-2017:** Austrian EHRA NCS representative
- **2016-2025:** Reviewer (2016-25), and Associate Editor (2025), Europace Journal
- **2016-2025:** Fellow of EHRA
- **2016-2020:** Member, EHRA Scientific Initiatives Committee
- **2017:** Writing Committee Member, ESC/EHRA Subclinical AF Consensus Document
- **2018-2025:** EHRA Recognized Training Center
- **2018-2020:** EHRA Congress Scientific Programme Committee
- **2019-2020:** Writing Committee Member, EHRA Position Statement Sports & Arrhythmias
- **2020-2022:** Member, EHRA National Cardiac Society Committee
- **2022-2025:** Member, EHRA Congress Mentorship Program
- **2022-2024:** Co-Chair (22-24), and Chair (24-26), EHRA National Cardiac Society Committee
- **2023-2025:** Co-Chair (23-25), and Chair (25-27), EHRA ATLAS Project
- **2025-2026:** Chair, EHRA Consensus Statement on same-day-discharge procedures
- **2025-2026:** Writing Committee Member, EHRA PFA Scientific Statement

ESC: Member since 2003; FESC since 2014; ESC Guideline Reviewer since 2017; ESC ATLAS Writing Committee Member since 2023, ESC Mentorship Program since 2024; ESC Membership Committee and Data Science Committee (both as EHRA delegate) since 2024;

Austrian National Cardiac Society: Member since 2003; Chair EP Working group 2015-17; Board member since 2016; NCS & Congress Secretary 2022-24; President 2025-27;





4. Why are you motivated to join the EHRA Executive Board (250 words max)?

It is my deep personal conviction that our most important task as physicians is to provide **excellent care for our patients** every day. Alongside this, a commitment to **education of young fellows** and peers and to advancing research is a vital part of our mission.

Beyond this clinical and academic calling, contributing to an association like EHRA is, for me, both a way of giving back and a **natural continuation of the opportunities and growth** I have experienced within this remarkable community. Applying for the Treasurer position is a decision I have considered carefully, knowing the responsibility it carries, but also the privilege it represents.

Over the years, I have met and worked with colleagues from across Europe, from **Kazakhstan to North Macedonia, from Estonia to Tunisia**, and many other countries, through mentoring programs, training courses, EHRA joint sessions, and the ATLAS project. These experiences have shown me the importance of representation, dialogue, and shared learning within our society. They have also reinforced my belief that EHRA must continue to support education, collaboration, and innovation in electrophysiology across all member countries.

As EHRA Treasurer, I would be honored to **serve as one of the voices representing our members**, physicians, allied professionals, and researchers, and to be approachable and available to support their needs. I believe that sound **financial stewardship, transparency, and strategic resource allocation** are essential to sustaining EHRA's impact and growth.

Finally, I have learned that **EHRA's success depends on teamwork**: from the dedicated staff and leadership team to the many committees, task forces, and members across nationalities. Working within and for EHRA feels right and rewarding. I can assure you that EHRA and its members will have my full commitment to this important task.



5. How will you combine your EHRA position with your daily clinical/research workload?

Please note that we expect you to:

- Have an active career at the time of taking office
 - Be on clinical practice (for at least 30%) at the time of application
-

Throughout my professional career, I have had the privilege of working in an environment that allows me **to combine my role as a full-time physician and researcher** at the Medical University of Graz with my engagement in professional societies, particularly EHRA.

My institution actively supports such activities, and I plan to **integrate my EHRA responsibilities within my designated research and teaching time**, which comprises approximately 20% of my overall workload (equivalent to one day per week).

I am also fortunate to lead an **outstanding clinical team and a dedicated research group** - colleagues who are highly trained, collaborative, and committed to ensuring the continuity and safety of patient care. Together, we coordinate responsibilities to allow for my participation in EHRA activities, including regular online meetings and committee work (typically one to two hours daily, when required).

I am deeply grateful to my family, my wife and our two children, for their unwavering support throughout my professional journey. Their encouragement enables me to fully engage in these responsibilities.

These arrangements have been **part of my routine for many years**, whether as chair of the EHRA National Cardiac Society Committee or in other leadership positions. I am therefore confident that I can dedicate the necessary time and focus to fulfill the duties of **EHRA Treasurer** with the attention and commitment the position deserves.



6. Please list your conflicts of interest

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
 - Industry Employee: 0%
 - Company (one company): Biotronik
 - Product or therapeutic area: Speaker Fee & consultancy
 - <10 K€/year

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
 - Industry Employee: 0%
 - Company (one company): Boston Scientific
 - Product or therapeutic area: Speaker Fee & consultancy
 - <10 K€/year

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
 - Industry Employee: 0%
 - Company (one company): Abbott
 - Product or therapeutic area: Speaker Fee & consultancy
 - <10 K€/year

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
 - Industry Employee: 0%
 - Company (one company): Boehringer Ingelheim
 - Product or therapeutic area: Speaker Fee

- <10 K€/year

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
 - Industry Employee: 0%
 - Company (one company): Zoll Medical
 - Product or therapeutic area: Speaker Fee
 - <10 K€/year

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
 - Industry Employee: 0%
 - Company (one company): Johnson & Johnson
 - Product or therapeutic area: Speaker Fee & consultancy
 - <10 K€/year



- Payments to your institution (speaker fees, honoraria, advisory board fees, consultancy, activities executed by your department for the sponsor or investigator initiated and funded by an unconditional grant from the sponsor...) – None
- Receipts of royalties for intellectual property - None

Position of influence declaration:

- Direct substantial shareholding or direct financial interest in healthcare, media, education companies or companies in relationship (suppliers or in competition with ESC or in contradiction with ESC mission):
None
- Employment in healthcare institution (part time or full time): None besides my occupation at Medical University Graz, Austria
- Membership or affiliation to political/pressure group associations related to the field of cardiology:
None
- Any potential interest related to the position applied for: None
- Nothing to declare: Yes